Skip to main content

Table 2 Golimumab and placebo effect estimates

From: Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies

Outcome

Fixed effect

Value

Standard error

p value

DAS

Baseline

5.931

0.057

0.000

 

GOL

−1.892

0.054

1.760Ă—10−241

 

PBO

−0.640

0.058

5.277Ă—10−28

lCRP

Baseline

1.246

0.022

0.000

 

GOL

−0.482

0.024

7.423Ă—10−88

 

PBO

−0.116

0.024

1.479Ă—10−6

rSJC

Baseline

3.752

0.063

0.000

 

GOL

−1.799

0.059

3.150Ă—10−191

 

PBO

−0.690

0.065

9.436Ă—10−26

rTJC

Baseline

4.992

0.077

0.000

 

GOL

−1.876

0.068

1.149Ă—10−159

 

PBO

−0.657

0.074

6.040Ă—10−19

  1. Fixed effect estimates of baseline disease state, GOL effect size, and PBO effect size derived from linear mixed models that used various outcomes (e.g., DAS, lCRP, etc.) as response metric DAS Disease Activity Score, GOL golimumab, lCRP log transform of C-reactive protein metric, PBO placebo, rSJC square root of SJC, rTJC square root of TJC, SJC swollen joint count, TJC tender joint count